urmjУральский медицинский журналUral Medical Journal2949-4389Ural State Medical University10.25694/URMJ.2018.12.27urmj-395Research ArticleПСИХИАТРИЯМаркеры фиброза в стратификации риска фибрилляции предсердий у пациентов с артериальной гипертонией и некоронарогенной патологиейRole fibrosis markers to stratify risk of atrial fibrillation in patients with arterial hypertension and ekstakardialnoy pathologyХидироваЛюдмила ДаудовнаKhidirovaL. D.h_ludmila73@mail.ruЯхонтовД. А.YakhontovD. A.noemail@neicon.ruЗенинС. А.ZeninS. A.noemail@neicon.ruГБОУ ВПО Новосибирский государственный медицинский университет Минздрава России; Новосибирский Областной Кардиологический Клинический ДиспансерRussian Federation201814042021012165169Copyright © Хидирова Л.Д., Яхонтов Д.А., Зенин С.А., 20212021Хидирова Л.Д., Яхонтов Д.А., Зенин С.А.Khidirova L.D., Yakhontov D.A., Zenin S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.umjusmu.ru/jour/article/view/395

Цель исследования - изучить роль маркеров фиброза (галектина-3 и NT-proBNP) в стратификации риска фибрилляции предсердий у больных с артериальной гипертонией в сочетании с экстракардиальными заболеваниями. (ФП). Материалы и методы. В проспективном когортном исследовании наблюдались 140 мужчин 35-65 лет с АГ и ФП (пароксизмальная и персистирующая форма), из них 57пациентов с АГ, ФП и хроническим обструктивным заболеванием легких (ХоБЛ) и 83 пациента с АГ, ФП без сопутствующей патологии (контроль). Всем обследованным выполнены антропометрия, исследования липидного спектра, Эхокг. Уровни галектина-3 и NT-proBNP в сыворотке крови оценивались методом иммуноферментного анализа. результаты. Уровень галектина-3 в сыворотке крови у больных АГ с ФП и ХОБЛ был выше - 36.02 нг / мл, чем в группе контроля - 19.23 нг / мл, р=0.001. Средний уровень NT-proBNP во всех исследуемой группе оказался достоверно выше и составил 123,8 пг / мл, р<0.001, по сравнению с группой контроля 67.99 пг / мл. Заключение. Маркеры фиброза галектин-3 и NT-proBNP в сыворотке крови у больных с фибрилляцией предсердий и артериальной гипертонией в сочетании с хроническим обструктивным заболеванием легких выше, чем у пациентов с фибрилляцией предсердий и артериальной гипертонии

The aim of the study was to study the role of fibrosis markers (galectin - 3 and NT-proBNP) in stratification of atrial fibrillation risk in patients with arterial hypertension in combination with extracardial diseases. Materials and methods. In a prospective cohort study, 140 men aged 35-65 years with hypertension and AF (paroxysmal and persistent form), 57 - AH, AF and chronic obstructive pulmonary disease (COPD) and 83 patients with hypertension, AF without comorbidity (control) were observed. Serum galectin-3 and NT-proBNP levels were assessed by enzyme immunoassay. Anthropometry, lipid spectrum and Echocardiography studies were performed for all examined patients. Results. The level of galectin-3 in blood serum of patients with AF and COPD was higher-36.02 ng / ml. than in the control group-19.23 ng / ml, p=0.001. The average level of NT-proBNP in all the study group was significantly higher and amounted to 123.8 PG / ml, p<0.001, compared with the control group 67.99 PG / ml. Conclusion. Markers of fibrosis galectin-3 and NT-proBNP in serum of patients with atrial fibrillation and arterial hypertension in combination with chronic obstructive pulmonary disease are higher than in patients with atrial fibrillation and arterial hypertension

фибрилляция предсердийартериальная гипертонияхроническая обструктивная болезнь легкихatrial fibrillationhypertensionhypothyroidismchronic obstructive pulmonary diseaseReferencesSavelieva I, Camm J. Update on atrial fibrillation: part I. Clin. Cardiol. 2008; 31(2): 55-62.Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin. Cardiol. 2008; 31(2): 55-62.De Boer R.A. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011; 43(1): 60-68.De Boer R.A. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011; 43(1): 60-68.Jennifer E.H. et al. Galectin 3 and incident atrial fibrillation in the community. Am. Heart J. 2014; 167: 729-734.Jennifer E.H. et al. Galectin 3 and incident atrial fibrillation in the community. Am. Heart J. 2014; 167: 729-734.Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol. 2008; 1(1): 62-73.Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol. 2008; 1(1): 62-73.Menezes A.R., Lavie C.J., Di Nicolantonio J.J. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc. 2013; 88(4): 394-409.Menezes A.R., Lavie C.J., Di Nicolantonio J.J. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc. 2013; 88(4): 394-409.Akoum N, Marrouche N. Assessment and impact of cardiac fibrosis on atrial fibrillation. Curr Cardiol Rep. 2014; 16(8): 518.Akoum N, Marrouche N. Assessment and impact of cardiac fibrosis on atrial fibrillation. Curr Cardiol Rep. 2014; 16(8): 518.Beinart R et al. Сardiac magnetic resonance T1 mapping of left atrial myocardium. Heart Rhythm. 2013; 10(9): 1325-1331.Beinart R et al. Сardiac magnetic resonance T1 mapping of left atrial myocardium. Heart Rhythm. 2013; 10(9): 1325-1331.Weber KT et al. Aldosteronism in heart failure: a proinflammatory / fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets. 2003; 4(6): 505-516.Weber KT et al. Aldosteronism in heart failure: a proinflammatory / fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets. 2003; 4(6): 505-516.Earlings L.W., Sanders-van Wijk S., van Kraaij D.J. et al. Riskstrati fication with the use of serial N-terminal-pro-B-Type Natriuretic Peptide Measurments During admission and early after dischargein heart failure patients: post hoc analysis of the PRIMA Study // J. Cardiac. Fail. 2014. V. 20. P. 881-890. https://DOI.org/10.1093/eurheartj/ehs104Earlings L.W., Sanders-van Wijk S., van Kraaij D.J. et al. Riskstrati fication with the use of serial N-terminal-pro-B-Type Natriuretic Peptide Measurments During admission and early after dischargein heart failure patients: post hoc analysis of the PRIMA Study // J. Cardiac. Fail. 2014. V. 20. P. 881-890. https://DOI.org/10.1093/eurheartj/ehs104Troughton R.W., Frampton C.M., Brunner-La Rocca H.P. et al. Effectof B-type natriuretic peptide-guided treatment of chronic heartfailu re on total mortality and hospitalization: an individual patientmeta-analysis // Eur. Heart J. 2014. V. 35. P. 1559-1567. DOI: 10.21037/jxym.2017.12.02Troughton R.W., Frampton C.M., Brunner-La Rocca H.P. et al. Effectof B-type natriuretic peptide-guided treatment of chronic heartfailu re on total mortality and hospitalization: an individual patientmeta-analysis // Eur. Heart J. 2014. V. 35. P. 1559-1567. DOI: 10.21037/jxym.2017.12.02Lok D.J., Lok S.I., Bruggink-Andre de la Porte P. W. et al. Galectin-3is an independent marker for ventricular remodeling and mortalityin patients with chronic heart failure // Clin. Res. Cardiol. 2013.102. P. 103-110. DOI: 10.1007/s10557-014-6520-2Lok D.J., Lok S.I., Bruggink-Andre de la Porte P. W. et al. Galectin-3is an independent marker for ventricular remodeling and mortalityin patients with chronic heart failure // Clin. Res. Cardiol. 2013.102. P. 103-110. DOI: 10.1007/s10557-014-6520-2Otzturk D., Celik O., Satilmis S. et al. Association between serumgalectin-3 levels and coronary atherosclerosis and plaque burden / structure in patients with type 2 diabetes mellitus // Coron.Artery Dis. 2015. [Epub. ahead of print]. http://dx.DOI.org/10.1097/MCA.0000000000000252Otzturk D., Celik O., Satilmis S. et al. Association between serumgalectin-3 levels and coronary atherosclerosis and plaque burden / structure in patients with type 2 diabetes mellitus // Coron.Artery Dis. 2015. [Epub. ahead of print]. http://dx.DOI.org/10.1097/MCA.0000000000000252Yalcin M.U. et al. The association of serum galectin-3 levels with atrial electrical and structural remodeling. J Cardiovasc Electrophysiol. 2015;Yalcin M.U. et al. The association of serum galectin-3 levels with atrial electrical and structural remodeling. J Cardiovasc Electrophysiol. 2015;

The authors declare that there are no conflicts of interest present.